Table 2. Association of Clinical and Pathological Aspects With Overall Survival of 182 Patients With Hepatocellular Carcinoma.
| Variable | Total N/N event | Overall survival |
|||
|---|---|---|---|---|---|
| Univariate analysis |
Multivariate analysis |
||||
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age (years) | |||||
| ≤ 60 | 94/91 | Reference | 0.63 | NA | NA |
| > 60 | 88/86 | 1.07 (0.80 - 1.44) | |||
| Gender | |||||
| Female | 34/32 | Reference | 0.16 | NA | NA |
| Male | 148/45 | 1.31 (0.89 - 1.92) | |||
| Alcoholism | |||||
| No | 74/76 | Reference | 0.20 | NA | NA |
| Yes or ex | 108/106 | 1.21 (0.89 - 1.64) | |||
| Smoking | |||||
| No | 91/87 | Reference | 0.08 | Reference | 0.24 |
| Yes or ex | 91/90 | 1.30 (0.96 - 1.75) | 1.20 (0.87 - 1.64) | ||
| Obesity | |||||
| No | 149/144 | Reference | 0.52 | NA | NA |
| Yes | 33/33 | 1.13 (0.77 - 1.65) | |||
| NLRc | |||||
| ≤ 2.2 | 92/92 | Reference | 0.78 | NA | NA |
| > 2.2 | 88/83 | 1.04 (0.77 - 1.40) | |||
| PLRc | |||||
| ≤ 98,705 | 86/84 | Reference | 0.53 | NA | NA |
| > 98,705 | 86/84 | 1.10 (0.81 - 1.49) | |||
| LMRc | |||||
| ≤ 2.8 | 86/84 | Reference | 0.31 | NA | NA |
| > 2.8 | 87/85 | 1.17 (0.86 - 1.58) | |||
| SIRIc | |||||
| ≤ 1.07 | 86/85 | Reference | 0.72 | NA | NA |
| > 1.07 | 87/84 | 1.05 (0.77 - 1.43) | |||
| SIIc | |||||
| ≤ 307,786.3 | 86/84 | Reference | 0.90 | NA | NA |
| > 307,786.3 | 86/84 | 1.02 (0.75 - 1.38) | |||
| Type 2 diabetes | |||||
| No | 122/117 | Reference | 0.02* | Reference | 0.17 |
| Yes | 60/60 | 1.42 (1.03 - 1.94) | 1.26 (0.89 - 1.78) | ||
| AFP (ng/mL)c | |||||
| ≤ 157.0 | 86/82 | Reference | 0.04* | Reference | 0.03*a |
| > 157.0 | 85/84 | 1.34 (1.00 - 1.82) | 1.40 (1.03 - 1.91) | ||
| Hepatitis B | |||||
| Negative | 169/164 | Reference | 0.73 | NA | NA |
| Positive | 13/13 | 1.10 (0.62 - 1.94) | |||
| Hepatitis C | |||||
| Negative | 75/73 | Reference | 0.64 | NA | NA |
| Positive | 107/104 | 1.07 (0.79 - 1.44) | |||
| Child-Pugh score | |||||
| A | 151/146 | Reference | 0.009* | Reference | 0.02*b |
| B or C | 29/29 | 1.72 (1.14 - 2.59) | 1.64 (1.07 - 2.52) | ||
| Grade 3 toxicity | |||||
| Yes | 147/144 | Reference | 0.06 | Reference | 0.07 |
| No | 35/33 | 1.45 (0.99 - 2.13) | 1.44 (0.96 - 2.15) | ||
Bootstrapping analysis: aP = 0.02 and bP = 0.002. cThe number of individuals is different from the total number of the study (n = 182) because it was not possible to obtain consistent information about the variable in some patients. *P ≤ 0.05. AFP: alpha-foetoprotein; CI: confidence interval; HR: hazard ratio; LMR: lymphocyte-to-monocyte ratio; NA: variable not included in Cox’s multivariate analysis; NLR: neutrophil-to-lymphocyte ratio; PLR: platelet-to-lymphocyte ratio; SII: systemic inflammatory index; SIRI: systemic inflammation response index.